CEO of Tetraneuron, where she leads the development of innovative gene therapies for neurodegenerative diseases such as Alzheimer’s disease.
Mari Carmen Álvarez holds a PhD in Biology from the University of Valencia and has more than 15 years of experience in biotech leadership. She co-founded Valentia Biopharma, the first biotech spin-off of the University of Valencia, where she led the development of therapies for rare diseases.
She is currently the CEO of Tetraneuron, where she leads the development of innovative gene therapies for neurodegenerative diseases such as Alzheimer’s disease. In addition, she has participated in more than 10 international consortia and has led multifunctional teams.
